Sandy Spring Bank’s PTC Therapeutics PTCT Stock Holding History

Sandy Spring Bank’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$10.2K	Hold	200	–	–	﹤0.01%	833
2024 Q4	$9.03K	Buy	+200	New	+$8.56K	﹤0.01%	873

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sandy Spring Bank's PTCT Position: Q1 2025 in Review

Sandy Spring Bank held its PTC Therapeutics (PTCT) position steady in Q1 2025 at 200 shares worth $10.2K. The position accounts for ﹤0.01% of the portfolio, ranked #833.

Sandy Spring Bank first reported a position in PTCT in Q4 2024 and has held it in 2 quarters since. 261 funds tracked by Wall St. Rank hold PTCT as of Q1 2025.

Sandy Spring Bank held 200 shares of PTC Therapeutics worth $10.2K as of Q1 2025.
Sandy Spring Bank left its PTC Therapeutics share count unchanged in Q1 2025.
PTC Therapeutics made up ﹤0.01% of Sandy Spring Bank's portfolio in Q1 2025, its #833 holding.
Sandy Spring Bank first reported a position in PTC Therapeutics in Q4 2024 and has held it in 2 quarters since.
261 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2025.

Based on Sandy Spring Bank's 13F filing for Q1 2025, filed 12 May 2025.